Jeffrey McQueary, MD
Urogynecology and Reconstructive Pelvic Surgery · Bristol, TNNPI 1740283688
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.5%. Reporting peaked in 2021 at $2,786 and has fallen 81.0% since, to $530 in 2025.
Across 244 payments — averaging $35.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Coloplast$2K
- Medtronic$1K
- Astellas Pharma US Inc$1K
- Applied Medical Resources Corporation$817
- Boston Scientific$516
- plus $1K from 15 others
Across 13 payments — averaging $1105.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$14K
What the payments were for
- Consulting fees$1,06512%
- Speaking & faculty fees$1602%
- Travel & lodging$2,29127%
- Food & beverage$4,86457%
- Education$1802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 54 | $1,757 |
| Coloplast | 23 | $1,681 |
| Medtronic(2 entities) | 20 | $1,393 |
| Astellas Pharma US Inc | 60 | $1,270 |
| Applied Medical Resources Corporation | 4 | $817 |
| Boston Scientific | 28 | $516 |
| Sumitomo Pharma America, Inc. | 10 | $271 |
| AbbVie(2 entities) | 17 | $271 |
| Mayne Pharma Commercial LLC | 5 | $184 |
| Therapeuticsmd, Inc. | 1 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Duchesnay USA Incorporated | 4 | $53 |
| Pfizer | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Antares Pharma, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Medline Industries LP | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
| Amgen | 1 | $15 |
| Caldera Medical, Inc | 1 | $15 |
| Lupin Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GelPOINT V-Path$1,215
- ALTIS$1,065
- INTERSTIM$1,060
- Axonics r-SNM System$848
- Bulkamid$848
- BIJUVA$125
How this compares
$8,560 in reported general payments places this provider in the 65th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
See all urogynecology and reconstructive pelvic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 116 | $61,430 |
| GemtesaVibegron | 70 | $56,597 |
| Solifenacin Succinate | 522 | $44,154 |
| ElmironPentosan Polysulfate Sodium | 32 | $36,280 |
| Estradiol | 302 | $15,298 |
| Methenamine Hippurate | 151 | $9,563 |
| PremarinEstrogens, Conjugated | 24 | $6,602 |
| NitrofurantoinNitrofurantoin Macrocrystal | 201 | $4,098 |
| CefuroximeCefuroxime Axetil | 220 | $3,491 |
| Bethanechol Chloride | 79 | $3,332 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 136 | $2,256 |
| Desmopressin Acetate | 55 | $2,167 |
| Tamsulosin Hcl | 174 | $1,998 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 15 | $1,612 |
| Trimethoprim | 35 | $1,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,270 | $61,430116 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $271 | $56,59770 claims |
| PfizerPremarin | $46 | $6,60224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
Other urogynecology and reconstructive pelvic surgery in Bristol
- Tara AllenNashville$100K
- Barry JarnaginFranklin$57K
- C BowlingKnoxville$52K
- Rena AzarSouth Pittsburg$23K
- Marcy AbelNashville$22K
- Roland HuffakerJohnson City$17K
- Henry OkaforChattanooga$13K
- Carson KaeserChattanooga$10K
- Val VogtGermantown$6K
- Jill DanfordNashville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.